Imperial, Cambridge Innovation in £12m Storm series-A

Existing backer Cambridge Innovation Capital also took part in the round, alongside new backers Merck Ventures BV and Pfizer Venture Investments.

The fresh capital will be used for research into potential new cancer therapies, with a focus on ribonucleic acid (RNA) epigenetics.

Upon completion of the deal, Imperial will hold a 22.3% stake in Storm.

Previous funding
Imperial led a seed funding round for Storm (at the time known as Iceni Therapeutics) in May 2015.

Company
Founded as a spinout from the University of Cambridge, Storm focuses on therapeutic modulation of RNA modifying enzymes. RNA enzymes play a prominent role in the regulatory functions of cells and, according to Storm, their importance to the treatment of cancer is increasingly being understood and acknowledged.

People
Imperial Innovations – Rob Woodman (director of healthcare).
Cambridge Innovation Capital – Robert Tansley (investment director).
Storm Therapeutics – Tony Kouzarides, Eric Miska (founders).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture